Processa Pharmaceuticals, Inc.(PCSA)Earnings, Financials & Key Ratios

"Processa Pharmaceuticals remains a pre-revenue biotechnology entity characterized by a high-fixed cost structure, with quarterly R&D expenditures consistently ranging between $1.3 million and $2.4 million. The company's reliance on external capital to fund its clinical pipeline has led to significant shareholder dilution, evidenced by stock-based compensation reaching $431,000 in 2025Q2. Investors should monitor the critical liquidity position, as the current cash balance of $1.7 million against a history of multi-million dollar quarterly losses suggests an urgent need for additional financing."